PRMT3 promotes tumorigenesis by methylating and stabilizing HIF1α in colorectal cancer
Abstract Abnormal angiogenesis occurs during the growth of solid tumors resulting in increased vascular permeability to fluids and metastatic cancer cells. Anti-angiogenesis therapy for solid tumors is effective in the treatment of cancer patients. However, the efficacy of anti-angiogenesis therapy...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2021-11-01
|
| Series: | Cell Death and Disease |
| Online Access: | https://doi.org/10.1038/s41419-021-04352-w |
| _version_ | 1819045601728266240 |
|---|---|
| author | Xin Zhang Kexin Wang Xingbo Feng Jian Wang Yali Chu Chunmeng Jia Qingsi He Cheng Chen |
| author_facet | Xin Zhang Kexin Wang Xingbo Feng Jian Wang Yali Chu Chunmeng Jia Qingsi He Cheng Chen |
| author_sort | Xin Zhang |
| collection | DOAJ |
| description | Abstract Abnormal angiogenesis occurs during the growth of solid tumors resulting in increased vascular permeability to fluids and metastatic cancer cells. Anti-angiogenesis therapy for solid tumors is effective in the treatment of cancer patients. However, the efficacy of anti-angiogenesis therapy is limited by drug resistance. The findings of the current study showed that HIF1α R282 is methylated by PRMT3, which is necessary for its stabilization and oncogene function. Analysis showed that PRMT3-mediated tumorigenesis is HIF1α methylation-dependent. A novel therapeutic molecule (MPG-peptide) was used to inhibit HIF1α expression. These findings provided information on PRMT3 signaling pathway and HIF1/VEGFA signaling pathway and offer a novel therapeutic strategy for colorectal cancer, mainly for treatment of anti-angiogenesis resistance patients. |
| first_indexed | 2024-12-21T10:31:10Z |
| format | Article |
| id | doaj.art-07436146f32043ab840f3eddf1e19e60 |
| institution | Directory Open Access Journal |
| issn | 2041-4889 |
| language | English |
| last_indexed | 2024-12-21T10:31:10Z |
| publishDate | 2021-11-01 |
| publisher | Nature Publishing Group |
| record_format | Article |
| series | Cell Death and Disease |
| spelling | doaj.art-07436146f32043ab840f3eddf1e19e602022-12-21T19:07:12ZengNature Publishing GroupCell Death and Disease2041-48892021-11-01121111310.1038/s41419-021-04352-wPRMT3 promotes tumorigenesis by methylating and stabilizing HIF1α in colorectal cancerXin Zhang0Kexin Wang1Xingbo Feng2Jian Wang3Yali Chu4Chunmeng Jia5Qingsi He6Cheng Chen7Department of General Surgery, Qilu Hospital of Shandong UniversityDepartment of General Surgery, Qilu Hospital of Shandong UniversityDepartment of General Surgery, Central Hospital of Zaozhuang Coal Mining GroupDepartment of General Surgery, Jinan integrative medicine hospitalDepartment of General Surgery, Qilu Hospital of Shandong UniversityDepartment of General Surgery, Qilu Hospital of Shandong UniversityDepartment of General Surgery, Qilu Hospital of Shandong UniversityDepartment of General Surgery, Qilu Hospital of Shandong UniversityAbstract Abnormal angiogenesis occurs during the growth of solid tumors resulting in increased vascular permeability to fluids and metastatic cancer cells. Anti-angiogenesis therapy for solid tumors is effective in the treatment of cancer patients. However, the efficacy of anti-angiogenesis therapy is limited by drug resistance. The findings of the current study showed that HIF1α R282 is methylated by PRMT3, which is necessary for its stabilization and oncogene function. Analysis showed that PRMT3-mediated tumorigenesis is HIF1α methylation-dependent. A novel therapeutic molecule (MPG-peptide) was used to inhibit HIF1α expression. These findings provided information on PRMT3 signaling pathway and HIF1/VEGFA signaling pathway and offer a novel therapeutic strategy for colorectal cancer, mainly for treatment of anti-angiogenesis resistance patients.https://doi.org/10.1038/s41419-021-04352-w |
| spellingShingle | Xin Zhang Kexin Wang Xingbo Feng Jian Wang Yali Chu Chunmeng Jia Qingsi He Cheng Chen PRMT3 promotes tumorigenesis by methylating and stabilizing HIF1α in colorectal cancer Cell Death and Disease |
| title | PRMT3 promotes tumorigenesis by methylating and stabilizing HIF1α in colorectal cancer |
| title_full | PRMT3 promotes tumorigenesis by methylating and stabilizing HIF1α in colorectal cancer |
| title_fullStr | PRMT3 promotes tumorigenesis by methylating and stabilizing HIF1α in colorectal cancer |
| title_full_unstemmed | PRMT3 promotes tumorigenesis by methylating and stabilizing HIF1α in colorectal cancer |
| title_short | PRMT3 promotes tumorigenesis by methylating and stabilizing HIF1α in colorectal cancer |
| title_sort | prmt3 promotes tumorigenesis by methylating and stabilizing hif1α in colorectal cancer |
| url | https://doi.org/10.1038/s41419-021-04352-w |
| work_keys_str_mv | AT xinzhang prmt3promotestumorigenesisbymethylatingandstabilizinghif1aincolorectalcancer AT kexinwang prmt3promotestumorigenesisbymethylatingandstabilizinghif1aincolorectalcancer AT xingbofeng prmt3promotestumorigenesisbymethylatingandstabilizinghif1aincolorectalcancer AT jianwang prmt3promotestumorigenesisbymethylatingandstabilizinghif1aincolorectalcancer AT yalichu prmt3promotestumorigenesisbymethylatingandstabilizinghif1aincolorectalcancer AT chunmengjia prmt3promotestumorigenesisbymethylatingandstabilizinghif1aincolorectalcancer AT qingsihe prmt3promotestumorigenesisbymethylatingandstabilizinghif1aincolorectalcancer AT chengchen prmt3promotestumorigenesisbymethylatingandstabilizinghif1aincolorectalcancer |